| pubmed-article:7643625 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7643625 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:7643625 | lifeskim:mentions | umls-concept:C1517806 | lld:lifeskim |
| pubmed-article:7643625 | lifeskim:mentions | umls-concept:C0333117 | lld:lifeskim |
| pubmed-article:7643625 | lifeskim:mentions | umls-concept:C0023089 | lld:lifeskim |
| pubmed-article:7643625 | lifeskim:mentions | umls-concept:C0071126 | lld:lifeskim |
| pubmed-article:7643625 | lifeskim:mentions | umls-concept:C0681828 | lld:lifeskim |
| pubmed-article:7643625 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:7643625 | pubmed:dateCreated | 1995-9-20 | lld:pubmed |
| pubmed-article:7643625 | pubmed:abstractText | Microspectrofluorometry allows the analysis of fluorescent molecules such as anthracyclines in the nucleus of isolated living cells. Using this technique, we confirmed that the amount of doxorubicin or THP-doxorubicin incorporated into the nucleus was related to the resistant or sensitive character of K562 cells. It was then extended to the study of fresh leukemic cells and kinetic studies were performed allowing the calculation of the retention rate (RR) of anthracycline (THP-doxorubicin) into the cell nucleus. A reproducibility study confirmed the accuracy of the method. Blast cells collected in patients with acute myeloid (n = 22) or lymphoid (n = 8) leukemia, at diagnosis (n = 26), or in relapse (n = 4) have been studied. RR varied from 8 to 98% independently of the type of leukemia or the clinical status. RR did not correlate either with P-glycoprotein or with CD34 expression although this latter result should be confirmed on a higher number of subjects. Among 18 patients presenting with AML at diagnosis, 14 have been treated with intensive chemotherapy including anthracyclines; the only one who had resistant disease had the lowest RR value. In conclusion, the results obtained here show that microspectrofluorometry allows the performance of kinetic studies on fresh leukemic cells in order to quantify chemo-resistance phenomena related to drug transport. | lld:pubmed |
| pubmed-article:7643625 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7643625 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7643625 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7643625 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7643625 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7643625 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7643625 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7643625 | pubmed:issn | 0887-6924 | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:SimonGG | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:PotronGG | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:EtienneJ CJC | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:LartigueBB | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:PignonBB | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:ManfaitMM | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:MillotJ MJM | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:MorjaniHH | lld:pubmed |
| pubmed-article:7643625 | pubmed:author | pubmed-author:VilqueJ PJP | lld:pubmed |
| pubmed-article:7643625 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7643625 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:7643625 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7643625 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7643625 | pubmed:pagination | 1361-7 | lld:pubmed |
| pubmed-article:7643625 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:meshHeading | pubmed-meshheading:7643625-... | lld:pubmed |
| pubmed-article:7643625 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7643625 | pubmed:articleTitle | In vitro study of THP-doxorubicin retention in human leukemic cells using confocal laser microspectrofluorometry. | lld:pubmed |
| pubmed-article:7643625 | pubmed:affiliation | Unité d'Hématologie Clinique, Hôpital Robert Debre, Reims, France. | lld:pubmed |
| pubmed-article:7643625 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7643625 | pubmed:publicationType | In Vitro | lld:pubmed |
